

D. P. Marchi-Salvador,^a
L. B. Silveira,^b A. M. Soares^b and
M. R. M. Fontes^{a*}

^aDepartamento de Física e Biofísica-IB, UNESP, CP 510, CEP 18618-000, Botucatu-SP, Brazil, and ^bDepartamento de Biotecnologia, UNAERP, Ribeirão Preto/SP, Brazil

Correspondence e-mail: fontes@ibb.unesp.br

Received 1 April 2005

Accepted 26 August 2005

Online 13 September 2005

Crystallization and preliminary X-ray diffraction analysis of myotoxin I, a Lys49-phospholipase A₂ from *Bothrops moojeni*


A new myotoxic Lys49-phospholipase A₂ isolated from *Bothrops moojeni* snake venom has been crystallized. The crystals diffracted to 2.18 Å resolution and belong to space group C2. The unit-cell parameters are $a = 56.8$, $b = 125.0$, $c = 64.7$ Å, $\beta = 105.5^\circ$. Preliminary analysis indicates the presence of four molecules in the asymmetric unit. This may suggest a new quaternary structure for this Lys49-phospholipase A₂ in contrast to the dimeric and monomeric structures solved so far for this class of proteins.

1. Introduction

Bothrops moojeni is a snake found in southeastern Brazil that causes an important number of ophidian accidents (Ribeiro *et al.*, 1998). The acute muscle damage induced by bothropic venoms is mainly caused by one or two basic myotoxic phospholipases A₂ (PLA₂s; Gutiérrez & Lomonte, 1995) and may lead to permanent tissue loss, disability and amputation (Rosenfeld, 1971; Nishioka & Silveira, 1982). PLA₂s are also one of the enzymes involved in the production of eicosanoids. These molecules have physiological effects at very low concentrations, but an increase in their concentration can lead to inflammation (Needleman *et al.*, 1986). Thus, the study of specific PLA₂ inhibitors may be important for the production of structure-based anti-inflammatory agents. Consequently, the study of these proteins is an important issue from scientific, medical and social points of view.

Phospholipases A₂ (EC 3.1.1.4) belong to a superfamily of proteins that hydrolyze the *sn*-2 acyl groups of membrane phospholipids to release arachidonic acid and lysophospholipids. The PLA₂ superfamily is divided into 11 classes (Six & Dennis, 2000) of which five (I, II, III, V and X) are abundant in a variety of biological fluids, particularly pancreatic secretions, inflammatory exudates and reptile and arthropod venoms (Rosenberg, 1990). PLA₂s of groups I and II are the major components of snake venoms, group II being predominant in bothropic venoms. In addition to their catalytic role, snake-venom PLA₂s show a broad range of relevant biological effects, including myotoxic, cytotoxic, oedema-inducing, artificial membrane disrupting, anticoagulant, neuromuscular, platelet-aggregation inhibiting, hypotensive, bactericidal, anti-HIV, anti-tumoral, antimalarial and antiparasitic effects (Gutiérrez & Lomonte, 1997; Ownby, 1998; Valentin & Lambeau, 2000).

Myonecrosis (muscle necrosis) may arise indirectly as a consequence of the vessel degeneration and ischaemia caused by haemorrhagic metalloproteases or as a direct effect of myotoxic PLA₂ homologues upon the plasma membranes of muscle cells (Rosenfeld, 1971). It is believed that myotoxins act on the sarcolemma membrane, thus inducing disorganization of phospholipids, loss of intracellular components and influx of Ca²⁺ ions (Díaz *et al.*, 1992). PLA₂s with skeletal muscle-damaging (myotoxicity) activity are widely distributed in venomous snakes and can be subdivided into at least three subclasses: (i) the Asp49 enzymes with high catalytic activity, (ii) the Ser49 enzymes with lower catalytic activity and (iii) the Lys49 enzymes, which do not display measurable catalytic activity (Shimohigashi *et al.*, 1995; Ownby *et al.*, 1999). The most abundant protein in many bothropic venoms is a natural mutant in which Asp49 is changed to Lys (subclass iii). This Asp49-to-Lys mutation prevents



calcium binding and the protein lacks catalytic activity. However, these Lys49-PLA₂s are capable of destroying the integrity of membranes and provoking release from liposomes (Rufini *et al.*, 1992). This process occurs in the absence of calcium ions without detectable lipid hydrolysis. One possibility is that these proteins are catalytically active towards an as yet unidentified phospholipid analogue.

Several crystal structures of Lys49-PLA₂s from the genus *Bothrops* have already been solved, revealing very similar fold patterns (Arni *et al.*, 1995, 1999; de Azevedo *et al.*, 1997, 1999; da Silva-Giotto *et al.*, 1998; Lee *et al.*, 2001; Magro *et al.*, 2003). However, new insights into the quaternary structure changes and the lack of phospholipase activity have recently been reported (Magro *et al.*, 2003; Soares *et al.*, 2004). The lack of catalytic activity of myotoxic Lys49-PLA₂s, which was first related solely to the fact that Lys49 occupies the position of the calcium ion in the catalytically active site of Asp49-PLA₂s, has also been attributed to Lys122, which interacts with the carbonyl of Cys29, hyperpolarizing the peptide bond between Cys29 and Gly30 (Lee *et al.*, 2001; Soares *et al.*, 2004). It has been observed that Lys122 is present in a conformation interacting with Cys29 for both monomers in those structures bound with a ligand (Watanabe *et al.*, 2005). However, considering the high sequential and structural homology of this class of proteins, further structural studies seem to be essential in order to obtain a deeper understanding of their lack of phospholipase activity and their pharmacological effects.

The isolation, biochemical/pharmacological characterization and amino-acid sequence of myotoxin I from *B. moojeni* (MjTX-I) has been reported (Soares *et al.*, 2000). Protein sequencing indicated that MjTX-I is a Lys49-PLA₂ and consists of 121 amino acids (MW = 13 669 Da; SWISS-PROT database code No. P82114). The protein showed local myotoxic and oedema-inducing activities in mice and is lethal by intraperitoneal injection. In addition, it is cytotoxic to myoblasts/myotubes in culture and disrupts negatively charged liposomes. MjTX-I does not present measurable enzymatic and anticoagulant activities (Soares *et al.*, 2000).

In the present paper, we describe the crystallization and X-ray diffraction data collection of MjTX-I, aiming to solve the structure and gain insights into functional aspects of this protein.

2. Experimental procedures

2.1. Purification

MjTX-I was isolated from *B. moojeni* snake venom by ion-exchange chromatography on CM-Sepharose (Soares *et al.*, 2000). The homogeneity of the toxin was assayed by SDS-PAGE, cathodic




Figure 1
Crystals of MjTX-I from *B. moojeni*.

Table 1

Data-collection and processing statistics.

Values in parentheses are for the highest resolution shell.

Unit-cell parameters (Å)	$a = 56.8, b = 125.0, c = 64.7, \beta = 105.5$
Space group	C2
Resolution (Å)	40–2.18 (2.28–2.18)
Unique reflections	22875 (2843)
Completeness (%)	97.0 (96.8)
$R_{\text{merge}}^{\dagger}$ (%)	6.0 (52.5)
Radiation source	Synchrotron (LNLS-CPr)
Data-collection temperature (K)	100
$\sigma(I)$ cutoff for data processing \ddagger	–3
$I/\sigma(I)$	19.2 (2.0)
Redundancy	3.8 (3.7)

$\dagger R_{\text{merge}} = \sum_{hkl} [\sum_i (I_{hkl,i} - \langle I_{hkl} \rangle)] / \sum_{hkl,i} \langle I_{hkl,i} \rangle$, where $I_{hkl,i}$ is the intensity of an individual measurement of the reflection with Miller indices h, k and l and $\langle I_{hkl} \rangle$ is the mean intensity of that reflection. Calculated for $I > -3\sigma(I)$. \ddagger Data processing used the *HKL* suite (Otwinowski & Minor, 1997).

PAGE, isoelectric focusing and immunoelectrophoresis (Soares *et al.*, 2000).

2.2. Crystallization

A lyophilized sample of MjTX-I was dissolved in ultrapure water at a concentration of 12 mg ml^{–1}. The sparse-matrix method (Jancarik & Kim, 1991) was used to perform initial screening of the crystallization conditions (Crystal Screens I and II, Hampton Research).

Small polycrystals of MjTX-I were obtained by the conventional hanging-drop vapour-diffusion method (McPherson, 1982), in which the protein solution was equilibrated against a reservoir containing 0.2 M magnesium chloride, 30% (w/v) polyethylene glycol 4000 and 0.1 M Tris-HCl pH 8.5 (Hampton Research Crystal Screen I, condition No. 6) after two months at 291 K. In order to improve the crystal quality, we made some modifications to the original reservoir solution. Better monocrystals were obtained with 0.15 M magnesium chloride, 32% (w/v) polyethylene glycol 4000 and 0.1 M Tris-HCl pH 8.5 and measured approximately 0.20 × 0.15 × 0.10 mm after approximately 12 months (Fig. 1).

2.3. X-ray data collection and processing

X-ray diffraction data from a single MjTX-I crystal were collected at a wavelength of 1.421 Å (at 100 K) using a synchrotron-radiation source (Laboratório Nacional de Luz Sincrotron, LNLS, Campinas, Brazil) and a MAR CCD imaging-plate detector (MAR Research). The crystal was mounted in a nylon loop and flash-frozen in a stream of nitrogen at 100 K using no cryoprotectant. The crystal-to-detector distance was 80 mm and an oscillation range of 1° was used; 146 images were collected. The data were processed to 2.18 Å resolution using the *HKL* program package (Otwinowski & Minor, 1997).

3. Results and discussion

The data-collection statistics are shown in Table 1. The data set is 97.0% complete at 2.18 Å resolution with $R_{\text{merge}} = 6.0\%$. The crystals belong to space group C2, with unit-cell parameters $a = 56.8, b = 125.0, c = 64.7$ Å, $\beta = 105.5^\circ$.

Packing-parameter calculations based on the protein molecular weight indicate the presence of three or four molecules in the asymmetric unit. This corresponds to a Matthews coefficient (Matthews, 1968) of 2.0 Å³ Da^{–1} with a solvent content of 54.5% or 2.7 Å³ Da^{–1} with a solvent content of 39.3% for three and four molecules in the asymmetric unit, respectively. To evaluate the local




Figure 2
Self-rotation function projection of the $\kappa = 180^\circ$ section for MjTX-I calculated using POLARRFN (Collaborative Computational Project, Number 4, 1994). Spherical polar angles are defined as follows: φ , the angle from the Cartesian x axis (a) on the xy plane (ab); ω , the angle from z axis (c); κ , the rotation around the axis defined by $\varphi\omega$.

symmetry of MjTX-I, the self-rotation function was calculated between 15 and 3.5 Å resolution applying an integration radius of 20 Å with the program POLARRFN (Collaborative Computational Project, Number 4, 1994). The $\kappa = 180^\circ$ self-rotation function projection in the ab plane (Fig. 2) reveals a peak at $\varphi = 90$ and -90° on the circumference arising from the crystallographic twofold axis. The presence of two peaks with similar height (*A* and *B*) suggests the presence of two twofold non-crystallographic symmetry (NCS) axes, which is compatible with 222 symmetry and a tetramer in the asymmetric unit. This leads to a new quaternary structure for MjTX-I in contrast to the dimeric (Arni *et al.*, 1995; de Azevedo *et al.*, 1997, 1999; da Silva-Giotto *et al.*, 1998; Lee *et al.*, 2001; Magro *et al.*, 2003) and monomeric (Arni *et al.*, 1999) Lys49-phospholipase A_2 structures solved to date.

Efforts are being made towards molecular-replacement solution using the AMoRe program (Navaza, 1994) with the coordinates of several Lys49-PLA₂s.

This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação para o Desenvolvimento da UNESP (FUNDUNESP) and Laboratório Nacional

de Luz Síncrotron (LNLS). We thank Dr G. Oliva (IFSC-USP) for useful discussions.

References

- Arni, R. K., Fontes, M. R. M., Barberato, C., Gutiérrez, J. M., Díaz-Oreiro, C. & Ward, R. J. (1999). *Arch. Biochem. Biophys.* **366**, 177–182.
- Arni, R. K., Ward, R. J. & Gutiérrez, J. M. (1995). *Acta Cryst.* **D51**, 311–317.
- Azevedo, W. F. de Jr, Ward, R. J., Gutiérrez, J. M. & Arni, R. K. (1999). *Toxicon*, **37**, 371–384.
- Azevedo, W. F. de Jr, Ward, R. J., Lombardi, F. R., Giglio, J. R., Soares, A. M., Fontes, M. R. M. & Arni, R. K. (1997). *Protein Pept. Lett.* **4**, 329–334.
- Collaborative Computational Project, Number 4 (1994). *Acta Cryst.* **D50**, 760–763.
- Díaz, C., Gutiérrez, J. M. & Lomonte, B. (1992). *Arch. Biochem. Biophys.* **298**, 135–142.
- Gutiérrez, J. M. & Lomonte, B. (1995). *Toxicon*, **33**, 1405–1424.
- Gutiérrez, J. M. & Lomonte, B. (1997). *Venom Phospholipase A₂ Enzymes: Structure, Function and Mechanism*, edited by R. M. Kini, pp. 321–352. Chichester: John Wiley & Sons.
- Jancarik, J. & Kim, S.-H. (1991). *J. Appl. Cryst.* **24**, 409–411.
- Lee, W. H., da Silva-Giotto, M. T., Marangoni, S., Toyama, M. H., Polikarpov, I. & Garratt, R. C. (2001). *Biochemistry*, **40**, 28–36.
- McPherson, A. (1982). *Preparation and Analysis of Protein Crystals*. New York: Wiley.
- Magro, A. J., Soares, A. M., Giglio, J. R. & Fontes, M. R. M. (2003). *Biochem. Biophys. Res. Commun.* **311**, 713–720.
- Matthews, B. W. (1968). *J. Mol. Biol.* **33**, 491–497.
- Navaza, J. (1994). *Acta Cryst.* **A50**, 157–163.
- Needleman, P., Turk, J., Jakschik, B. A., Morrison, A. R. & Lefkowitz, J. B. (1986). *Annu. Rev. Biochem.* **55**, 69–102.
- Nishioka, S. A. & Silveira, P. V. P. (1982). *Am. J. Trop. Med. Hyg.* **47**, 805–810.
- Otwinowski, Z. & Minor, W. (1997). *Methods Enzymol.* **276**, 307–326.
- Ownby, C. L. (1998). *J. Toxicol. Toxin Rev.* **17**, 1003–1009.
- Ownby, C. L. H., Selistre de Araujo, S., White, S. P. & Fletcher, J. E. (1999). *Toxicon*, **37**, 411–445.
- Ribeiro, L. A., Albuquerque, M. J. & Pires de Campos, V. A. F. (1998). *Rev. Assoc. Med. Bras.* **44**, 312–318.
- Rosenberg, P. (1990). *Handbook of Toxinology*, edited by W. Shier & D. Mebs, pp. 67–277. New York: Marcel Dekker.
- Rosenfeld, G. (1971). *Venomous Animals and their Venoms II*, edited by W. Bucherl, E. Buckley & V. Deulofeu, pp. 345–384. New York: Academic Press.
- Rufini, S., Cesaroni, P., Desideri, R. F., Gubensek, F., Gutiérrez, J. M., Luly, P., Maassoud, R., Morero, R. & Pedersen, J. Z. (1992). *Biochemistry*, **31**, 12424–12430.
- Shimohigashi, Y., Tani, A., Matsumoto, H., Nakashima, K. & Yamaguchi, Y. (1995). *J. Biochem.* **118**, 1037–1044.
- Silva-Giotto, M. T. da, Garratt, R. C., Oliva, G., Mascarenhas, Y. P., Giglio, J. R., Cintra, A. C. O., de Azevedo, W. F. Jr, Arni, R. K. & Ward, R. J. (1998). *Proteins*, **30**, 442–454.
- Six, D. A. & Dennis, E. A. (2000). *Biochim. Biophys. Acta*, **1488**, 1–19.
- Soares, A. M., Andrião-Escarso, S. H., Angulo, Y., Lomonte, B., Gutiérrez, J. M., Marangoni, S., Toyama, M. H., Arni, R. K. & Giglio, J. R. (2000). *Arch. Biochem. Biophys.* **373**, 7–15.
- Soares, A. M., Fontes, M. R. M. & Giglio, J. R. (2004). *Curr. Org. Chem.* **8**, 1677–1690.
- Valentin, E. & Lambeau, G. (2000). *Biochimie*, **82**, 815–831.
- Watanabe, L., Soares, A. M., Ward, R. J., Fontes, M. R. M. & Arni, R. K. (2005). *Biochimie*, **87**, 161–167.